Influence of Combination with 1q21 Amplification or-No in Patients with Newly Diagnosed MM on the Clinical Effecacy of Bortezomib-based induction chemotherapy and Long-Term Prognosis of Patients.
10.19746/j.cnki.issn.1009-2137.2020.04.028
- Author:
Wei-Wei GU
1
;
Ji-Song WANG
1
;
Kun MU
1
;
Gang REN
2
Author Information
1. Department of Oncology, People's Hospital of Jinan City, Jinan, 271100, Shandong Province, China.
2. Department of Oncology, People's Hospital of Jinan City, Jinan, 271100, Shandong Province, China,E-mail: lwrengang62@163.com.
- Publication Type:Journal Article
- MeSH:
Antineoplastic Combined Chemotherapy Protocols;
Bortezomib;
therapeutic use;
Disease-Free Survival;
Humans;
Induction Chemotherapy;
Multiple Myeloma;
drug therapy;
Prognosis;
Retrospective Studies;
Treatment Outcome
- From:
Journal of Experimental Hematology
2020;28(4):1251-1255
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the influence of influence of combination with 1q21 amplification or-no in patients with newly diagnosed MM on the clinical effecacy of bortezomib-based induction chemotherapy and long-term prognosis of patients.
METHODS:148 patients with newly diagnosed MM treated from January 2010 to May 2018 were selected and divided into 2 groups: group A (70 patients) without 1q21 amplification and group B (78 patients) with 1q21 amplification; and the survival benefit and influence on clinical efficacy of bortezomib were compared between 2 groups, and the factors influencing clinical prognosis in the patients with newly diagnosed MM were analyzed.
RESULTS:The median PFS and OS of patients in B group were significantly shorter than those in group A (P＜0.05). There was no significant difference in the median OS and PFS between patients with 1q21 amplification copies number =3 and ＞3 (P＞0.05). Multivariate Cox model analysis indicated that the adverse factors for OS were ISS staging, Hb levels, β2 microglobulin levels and 1q21 amplification respectively, and the adverse factors for PFS were Hb levels and 1q21 amplification respectively in patients with newly diagnosed MM (P＜0.05). The very good partial remission rate of newly diagnosed MM patients with 1q21 amplification and bortezomib-based induction chemotherapy were significantly higher than that in the patients without bortezomib-based induction chemotherapy (P＜0.05). The median PFS time of newly diagnosed MM patients with 1q21 amplification and auto-HSCT after bortezomib-based induction chemotherapy was significantly longer than that of patients without auto-HSCT (P＜0.05).
CONCLUSION:1q21 amplification should be the independent risk factor for poor prognosis of patients with newly treated MM. The application of bortezomib-containing induction chemotherapy in patients with 1q21 amplification can efficiently improve the remission rate, while auto-HSCT consolidation therapy may prolong patients' PFS.
